MCM
PRNB

Matarin Capital Management’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Matarin Capital Management’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,195
Closed -$1.11M – 262
2019
Q4 		$1.11M Sell
20,195
-1,058
-5% -$39.5K 0.11% 179
2019
Q3 		$600K Sell
21,253
-11,261
-35% -$413K 0.05% 219
2019
Q2 		$1.08M Buy
+32,514
New +$1.02M 0.08% 207

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Matarin Capital Management's PRNB Position: Q1 2020 in Review

Matarin Capital Management sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q1 2020, closing a stake of 20,195 shares — an estimated $1.11M sold.

Matarin Capital Management first reported a position in PRNB in Q2 2019 and held it in 3 quarters. The position peaked at $1.11M in Q4 2019. 118 funds tracked by Wall St. Rank hold PRNB as of Q1 2020.

  • Matarin Capital Management reported no remaining Principia Biopharma Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Matarin Capital Management sold 20,195 Principia Biopharma Inc. Common Stock shares in Q1 2020, an estimated $1.11M.
  • Matarin Capital Management first reported a position in Principia Biopharma Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Matarin Capital Management's Principia Biopharma Inc. Common Stock position peaked at $1.11M in Q4 2019.
  • 118 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q1 2020.

Based on Matarin Capital Management's 13F filing for Q1 2020, filed 27 Apr 2020.